Abstract. The clinicopathological value and exploration of the potential molecular mechanism of microRNA-183-5p (miR-183-5p) have been investigated in various cancers; however, to the best of the author's knowledge, no similar research has been reported for bladder cancer. In the present study, it was revealed that the expression level of miR-183-5p was notably increased in bladder cancer tissues compared with adjacent non-cancerous tissues (P=0.001) and was markedly increased in the tissue samples of papillary, pathological T stage (T0-T2) and pathological stage (I-II) compared with tissue samples of their counterparts (P=0.05), according to data from The Cancer Genome Atlas. Receiver operating characteristic analysis revealed the robust diagnostic value of miR-183-5p for distinguishing bladder cancer from non-cancerous bladder tissues (area under curve=0.948; 95% confidence interval: 0.919-0.977). Amplification and deep deletion of miR-183-5p were indicated by cBioPortal, accounting for 1% (4/412) of bladder cancer cases. Data from YM500v3 demonstrated that compared with other cancers, bladder cancer exhibited high expression levels of miR-183-5p, and miR-183-5p expression in primary solid tumors was much higher compared with solid normal tissues. A meta-analysis indicated that miR-183-5p was more highly expressed in bladder cancer samples compared with normal counterparts. A total of 88 potential target genes of miR-183-5p were identified, 13 of which were discerned as hub genes by protein-protein interaction. The epithelial-to-mesenchymal transition pathway was the most significantly enriched pathway by FunRich (P= 0.0001). In summary, miR-183-5p may participate in the tumorigenesis and development of bladder cancer via certain signaling pathways, particularly the epithelial-to-mesenchymal transition pathway. However, the exact molecular mechanism of miR-183-5p in bladder cancer must be validated by in vitro and in vivo experiments.
Introduction
Due to the high mortality and recurrence, bladder cancer (BC) remains one of the most frequently appearing cancer of the urinary system (1) . In America, ~79,030 new patients with BC will be diagnosed in 2017, including 60,490 males and 18,540 females (2) . Although there has been huge progress in therapeutic methods, such as cystectomy and adjuvant treatments, BC occupies one of the most common cancers with a high mortality and recurrence rate worldwide (1) . Among the patients with recurrent BC, more than one-tenth continue to develop into higher phases, such as muscle invasion and metastasis (3) (4) (5) . The discovery of cancer at an advanced stage could lead to a poor prognosis. It is a prioritized event to explore the exact mechanism of BC to improve the sensitivity and specificity of early diagnosis. In recent years, evidence accumulation in the knowledge of molecular biology and application of bioinformatics has provided good opportunities to understand BC comprehensively via bioinformatic analysis, such as the application of microRNAs (miRNAs) (6) (7) (8) .
miRNAs, a type of short non-coding RNA ~22 nucleotides in length, facilitate mRNA degradation by sequence-specific combination with mRNA, providing new strategies on diagnosis and treatment of cancers (9) (10) (11) (12) . miRNAs have been found to participate in the expression regulation of hub genes related to the development and progression of tumors, including BC (13) (14) (15) (16) . The abnormally expressed and genetically altered miRNAs have been reported to be involved in the Clinical value and potential pathways of miR-183-5p in bladder cancer: A study based on miRNA-seq data and bioinformatics analysis biological process of BC, including miR-199a-5p, miR-1-3p, miR-9, miR-182 and miR-200b (17) (18) (19) . miR-183-5p, located on chromosome 7q32.2, has been studied in various types of cancers, such as human breast cancer (20) , esophageal squamous cell carcinoma (21) , esophageal squamous cell carcinoma (22) , gastric cancer (23) , human pancreatic adenocarcinoma (24) and melanoma (25) . The expression of miR-183 in BC patients was higher in tissues (26) (27) (28) and serum (29) and showed a moderate value of the BC diagnosis (27) . However, no functional study of miR-183-5p in BC has been reported previously. Most of the published studies on miR-183-5p tended to focus on the higher expression of miR-183-5p in samples from patients with BC, including tissues, urine and serum, than in samples from normal individuals, or the diagnostic efficiency of miR-183-5p. However, the clinical significance, as well as the promising target genes of miR-183-5p in BC, needs to be explored (26) (27) (28) (29) . In addition, the studies mentioned above were based on a small scale of BC patient cohorts, and big data analysis was needed to uncover the real role of miR-183-5p in BC.
Therefore, in the present study, we first attempted to investigate the clinical significance of the expression level and genetic alteration of miR-183-5p in BC based on the data from The Cancer Genome Atlas (TCGA; https://cancergenome.nih.gov/), cBioPortal for Cancer Genomics (http://www.cbioportal.org/), Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/), and YM500v3 (http://driverdb.tms.cmu.edu.tw/ym500v3/). In addition, we identified potential target genes of miR-183-5p via differential expressed genes calculated by RNA-seq data from TCGA, predicting platforms and gene profiling post miR-183-5p overexpression in vitro. Further bioinformatic analyses, including the enrichment of functional annotation and biological pathway analyses, were performed to explore the possible roles of miR-183-5p in the tumorigenesis and progression of BC.
Materials and methods
The work flow of the present study is shown in Fig. 1 . Firstly, we evaluated the clinical significance of miR-183-5p in BC based on data from TCGA, cBioPortal, YM500v3 and PubMed. Secondly, the potential molecular mechanism of miR-183-5p in BC was explored via bioinformatic analysis with potential target genes overlapped with predicting target genes, lowexpression genes based on RNA-seq data from TCGA and downregulated genes from Gene Expression Omnibus (GEO).
Data acquisition and analysis. The miRNA sequencing data of miR-183 and clinical information of patients with BC were obtained from TCGA and contained 412 cases and 19 paracarcinoma tissues of counterparts as controls (30, 31) . Only 409 cases possessed the miRNA sequencing data and clinical information. The clinical information and follow-up data of these cases, including sex, body mass index (BMI), primary therapy outcome, pack number of cigarettes smoked per year, primary therapy outcome, diagnosis subtype, lymphovascular invasion, pathologic T stage, pathologic N stage, pathologic M stage, pathologic stage and new tumor events after initial treatment were also downloaded to analyze the correlation between miR-183 expression and clinical parameters (Table I) . Receiver operator characteristic curve (ROC) and Kaplan-Meier (K-M) analyses were used to assess the diagnostic and prognostic roles of miR-183.
Furthermore, the expression data and prognostic analysis of miR-183-5p were provided from database of YM500v3 (http://driverdb.tms.cmu.edu.tw/ym500v3/). The genetic alteration of miR-183 was validated from the cBioPortal database (http://www.cbioportal.org/). 
Meta

Prediction of the prospective target genes of miR-183-5p.
The prediction of miR-183-5p target genes was conducted with different bioinformatics tools, including miRWalk, MicroT4, miRanda, miRBridge, miRDB, miRMap, miRNAMap, PICTAR2, PITA, RNA22, RNAhybrid, TargetScan. Only 7,421 genes appearing for over 4 times among 12 platforms were regarded as potential target genes of miR-183-5p.
Potentially related genes of miR-183-5p in BC cells as detected by microarray. According to the information provided by GSE24782 microarray, a few human cancer cell lines, including BOY, T24, A498, PC3, DU145, FaDu, SAS, HSC3 and IMC3, were transfected with different miRNAs (miR-183-5p, miR-218, miR-145, miR-1 and miR-874). Based on the functional mechanism of miRNA, low-expression genes with a fold change (FC) <0.85 after transfected with miR-183-5p in BOY and T24 cells were regarded as potential target genes of miR-183-5p. A total of 3,163 genes were selected for further analysis.
Selection of low-expression genes based on RNA-seq dataset from TCGA. The RNA-seq dataset from TCGA contained 60,483 mRNAs, which were then used for the analysis of the differential expression with the R package of edgeR (32, 33) . Differentially expressed genes with the expression data missing in >10% samples were excluded. Due to the high expression of miR-183 in tumor tissues, low-expression genes were selected as the candidates of target genes of miR-183-5p. Therefore, 2,918 low-expression genes with log2 FC<-1 were included.
Protein-protein interaction (PPI) analysis, Gene ontology (GO)
and biological pathway. PPI was conducted to identify the hub genes by STRING: Functional protein association networks (https://string-db.org/). Furthermore, to study the prospective biological effects of miR-183-5p in BC, the potential target genes of miR-183-5p were sent for GO and biological pathway analyses, which was performed via FunRich: Functional Enrichment analysis tool (34, 35) (http://www.funrich.org/).
Moreover, to validate the reliability of the potential target genes of miR-183-5p, correlation analysis between the mRNA expression data of the prospective target genes of miR-183-5p enriched in the first pathway of the biological pathway and miR-183-5p expression data were performed. The comparisons of potential target genes between BC and non-cancerous tissues were also carried out.
Statistical analysis. The miR-183-5p expression data are displayed as the means ± standard deviation (SD). Student's t-test for independent samples was performed to evaluate the relationship between miR-183 and clinical parameters. Pearson correlation analysis and Student's t-test were performed for the verification of genes significantly enriched in biological pathways. P<0.05 was considered to indicate a statistically significant difference.
Results
Clinical significance of miR-183. Due to the lack of expression data of mature miR-183-5p in the dataset of TCGA, the comparison of the stem-loop mir-183 expression level between BC and adjacent non-cancerous tissues was provided. The miR-183 expression level in BC tissues was notably higher than that in adjacent tissues ( Fig. 2A ; Table I ). High expression of miR-183 was notably associated with the papillary subtype (t=-3.353, P=0.001), low pathologic T stage (t=2.106, P=0.036), and early pathologic stage (t=2.533, P=0.012). However, no remarkable differences were found between miR-183 expression and sex, BMI, primary therapy outcome, pack number of cigarettes smoked per year (mean), primary therapy outcome, lymphovascular invasion present, pathologic N stage, pathologic M stage or new tumor event after initial treatment (Table I) .
ROC curve analysis showed that the area under the curve (AUC) was 0.948 (95% CI: 0.919-0.977) with 83.6% sensitivity and 100% specificity (Fig. 2B ), indicating that a high expression level of miR-183 may be an ideal marker for BC diagnosis. Furthermore, the K-M curve uncovered that no significant difference in the survival time was noted between patients in the low and high miR-183 expression groups (P=0.861) (Fig. 2C) .
The expression of miR-183-5p in primary solid tumors were much higher than that in solid normal tissues (Fig. 2D) , which was consistent with the result from TCGA ( Fig. 2A) . The miR-183-5p expression data in various cancers were provided in YM500v3 (Fig. 2E ). Compared with other cancers, BC exhibited higher expression levels of miR-183-5p. This finding again confirmed that there was no significant prognostic value of miR-183-5p in patients with BC (Fig. 2F) .
The data from cBioPortal revealed that miR-183 contained two kinds of genetic alterations, including amplification and deep deletion, accounting for 1% (4/412) of patients with BC (Fig. 2G ). In addition, no prominent correlation was found between miR-183 alteration and the outcome of BC patients, including overall survival or disease-free survival ( Fig. 2H and I ).
miR-183-5p expression level from GEO and literatures.
A total of 16 microarrays were obtained from GEO, including GSE20414, GSE20418, GSE2564, GSE31616, GSE31617, GSE36121, GSE39067, GSE39093, GSE40355, GSE48008, GSE50894, GSE59483, GSE81201, GSE83586, GSE84525 and GSE86411. Eventually, only GSE39093 was eligible, and the data were used for recalculation. The expression level of miR-183-5p (4.216±0.485) in 10 BC tissue samples was moderately higher than that in the 10 normal counterparts (3.825±0.460, P>0.05) (Fig. 3A) . A comprehensive search was performed in several literature databases; however, only one study provided normalized expression data. In detail, the expression of miR-183-5p in 104 urothelial carcinomas (4.225±0.414) was significantly higher than that in 31 normal bladder epitheliums (1.224±0.224, P<0.0001) (Fig. 3B) (27) . All of the eligible expression data of miR-183-5p extracted from TCGA, one GEO microarray and one literature research provided an overall SMD of 3.76 (0.34-7.19) as analyzed by STATA software (Fig. 3C) , suggesting that miR-183-5p was more highly expressed in samples from BC than in those from normal counterparts. The source of patients with BC and different detection methods may lead to strong heterogeneity.
Identification of the potential target genes of miR-183-5p.
In the present study, the overlapped genes from 3 subsets of genes, including predicted target genes, related potential target genes of miR-183-5p from GEO and low-expression genes from Table I . Correlation between miR-183 expression and clinical parameters. TCGA, were regarded as the potential target genes of miR-183-5p. Finally, 88 overlapped genes were obtained (Table II) .
Bioinformatic analyses of the target genes of miR-183-5p.
As shown in Fig. 4 , hub genes, which contained >3 connected lines, were identified, including estrogen receptor 1 (ESR1), melanogenesis-associated transcription factor (MITF), androgen receptor (AR), C-X-C motif chemokine ligand 12 (CXCL12), insulin-like growth factor 1 (IGF1), caveolin 1 (CAV1), DLC1 Rho GTPase activating protein (DLC1), fibroblast growth factor 2 (FGF2), EPH receptor A2 (EPHA2), Rho associated coiled-coil containing protein kinase 1 (ROCK1), Ras homolog family member B (RHOB), phospholipase C beta 4 (PLCB4) and tropomyosin 1 (TPM1) (single genes without connections are not shown) (Fig. 4) . The overlapped genes were also categorized in GO and biological pathway analyses using the software of FunRich: Functional Enrichment analysis tool. The top 5 pathways in molecular functions (MFs), such as cytoskeletal protein binding, protein threonine/tyrosine kinase activity, were displayed in Fig. 5A and Table III . In addition, the top 5 pathways of biological processes (BPs) (Fig. 5B ) and cellular component (CC) were also noted (P-value <0.05) ( Fig. 5C ; Table III) . Via the biological pathway analysis, we discovered that the epithelial-to-mesenchymal transition pathway was the most significantly enriched (P-value <0.00001) ( Fig. 5D ; Table III ).
Validation of potential target genes enriched in the epithelial-to-mesenchymal transition pathway by mRNA expression data from TCGA.
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Discussion
In the present study, the clinical role of miR-183-5p in BC was first evaluated according to the data from miRNA sequencing 'epithelial-to-mesenchymal transition' was the most remarkable one as defined by the FunRich: Functional Enrichment analysis tool, containing several genes ZFPM2, AKAP12, CLIC4, ZEB2, BNC2, CAV1, CXCL12, SOBP, TNS1, IGF1, SYNE1, PTX3 and WWTR1; among these genes, CAV1, CXCL12 and IGF1 were also identified as hub genes of miR-183-5p in BC by STRING: Functional protein association networks.
It has been fully demonstrated that miRNA expression levels could become reliable markers for the diagnosis and prognosis of cancers (36) . miR-183-5p is one of the attractive cancer-relative miRNAs that has been reported to play important roles in various cancers with remarkably high or low expression levels compared with normal tissues. A remarkably high expression of miR-183-5p that could promote the proliferation and restrain apoptosis in cells through targeting PDCD4 was reported in human breast cancer tissues compared with that in the adjacent noncancerous tissues (20) . A similar phenomenon and function of miR-183-5p was also reported in esophageal squamous cell carcinoma and glioblastoma multiforme (21) (22) (23) . Upregulation of oncogenic miR-183-5p was reported to enhance the ability of proliferation and metastasis in human pancreatic adenocarcinoma cells probably via targeting the SOCS-6 gene (24) . A notable lower expression of miR-183-5p was found in nasopharyngeal carcinoma and cervical cancer tissues, where miR-183-5p could act as the tumor suppressor by targeting MTA1 and MMP-9, respectively (37, 38) . Reduced expression of miR-183-5p was discovered in pancreatic ductal adenocarcinoma tissues; and significantly associated with tumor grade, metastasis and TNM stage. Patients with low expression of miR-183-5p tended to have notably worse overall survival than those with high expression of miR-183-5p expression (38) . Patients with low-expression of miR-183-5p tended to have a poor overall survival. miR-183-5p was involved in cell proliferation by regulating the expression of Bmi-1 (39) . Low-expression miR-183-5p was found in melanoma tissues and cells and was correlated with poor overall survival, while high-expression of miR-183-5p caused remarkable inhibition of cell growth in vitro and in vivo (25) . Thus, miR-183-5p could play different roles in various cancers. To date, only several studies were reported concerning the research of miR-183-5p in BC. It was validated that miR-183-5p expression in samples from patients with BC, including tissues (26, (40) (41) (42) , urine (27, 43) and serum (29) , were all prominently higher than that those in normal counterparts. In the present study, we revealed the consistent results in tissue samples.
Eissa et al performed ROC analysis of miR-183-5p expression in urine samples. However, only the sensitivity (71.3%) and specificity (88.9%) were provided (43). Yamada et al showed the result of ROC analysis (AUC=0.817; 95% CI: 0.752-0.872) with 74.0% sensitivity and 77.3% specificity, indicating a moderate diagnostic efficiency of miR-183-5p expression in urine, and they also found a significant correlation between miR-183-5p expression and clinical parameters, including tumor grade and pathological stage (P-value <0.05) (27) . In our study, ROC curve analysis showed a robust diagnostic efficiency of miR-183-5p in BC tissues (AUC=0.948; 95% CI: 0.919-0.977). The expression of miR-183-5p was markedly related to the diagnosis subtype, pathologic T stage and pathologic stage (P-value <0.05). However, K-M curve analysis showed no prognostic efficiency of miR-183-5p, based on the data from TCGA, YM500v3 and cBioPortal.
miR-183-5p was conformed to affect the biological behavior of cells by targeting different kind of proteins in various types of cancers, such as regulating cell proliferation by targeting PDCD4 in breast (44) and esophageal cancer (21) , and esophageal squamous cell carcinoma (22) , inhibiting tumorigenesis by targeting MTA1 in nasopharyngeal carcinoma (37) , promoting cell proliferation by targeting NEFL in glioblastoma multiforme (45) , and suppressing retinoblastoma cell growth by targeting LRP6 (46) . However, no study has reported the possible molecular mechanisms of miR-183-5p in BC. In the present, the potential target genes of miR-183-5p were obtained by the overlap of genes from 3 datasets, including the available predicting online tools, low-expression genes from TCGA and low-expression genes from microarray data after miR-183-5p mimic transfection.
The potential molecular mechanism of miR-183-5p in BC was explored. In total, 7,421 genes were predicted using the online predicting tool of miRwalk2.0. The low-expression genes from the RNA-seq data of TCGA with log2 FC <-1 were regarded as potential target genes of miR-183-5p, and 2,918 genes were involved. The GSE24782 microarray, which contained the data of differential-expressed genes after the overexpression of miR-183-5p in BOY and T24 cells, was reassessed to identify the downregulated genes with a fold change <0.85; 3,163 eligible genes were included. Consequently, 88 overlapped genes were identified and were more prone to be the target genes of miR-183-5p in BC. Next, bioinformatics analyses discovered that these potential target genes were enriched in several pathways involved in the tumorigenesis and development of BC. Forty-three genes were enriched in the pathway of cytoplasm, which ranked the 2nd most significant pathways in the cellular component (CC). The most significant pathway indicated in molecular function (MF) was the pathway of cytoskeletal protein binding. Several significant pathways relative to signal transduction or cell communication were involved in biological process (BP), such as calcium-mediated signaling, cell communication and signal transduction. The pathway of epithelial-to-mesenchymal tran sition was the most enriched pathway in the biological pathway, playing a crucial role in tumor progression with genes of ZFPM2, AKAP12, CLIC4, ZEB2, BNC2, CAV1, CXCL12, SOBP, TNS1, IGF1, SYNE1, PTX3 and WWTR1. The expression of these 13 target genes was negatively correlated with the expression of miR-183-5p in BC tissues. miR-183-5p was conformed to target the tumor suppressor AKAP12 and plays an important role in human hepatocarcinogenesis (47) . CAV1, CXCL12 and IGF1 were also identified as hub genes of miR-183-5p in BC which may deeply affect the generation and development of BC. However, rigorous experiments in vitro and in vivo are needed to confirm the potential molecular mechanism.
In summary, miR-183-5p may play critical roles in the tumorigenesis and development of BC; however, the clinical function of miR-183-5p in BC urgently requires exploration. Furthermore, several crucial pathways for miR-183-5p in BC were predicted by bioinformatics analysis. However, validation of the real molecular mechanisms of miR-183-5p in BC by well-designed and rigorous functional experiments is still needed.
